Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||MIW815 + Spartalizumab||Phase Ib/II||Actionable||In a Phase Ib trial, MIW815 (ADUS100), in combination with Spartalizumab (PDR001), demonstrated preliminary efficacy in PD-1 (PDCD1)-naive TNBC patients (J of Clin Oncol 37, 2019 (suppl; abstr 2507); NCT03172936).||detail...|
|PubMed Id||Reference Title||Details|
|Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.||Full reference...|